for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Catabasis Reports Edasalonexent Preserved Muscle Function And Substantially Slowed Duchenne Muscular Dystrophy Disease Progression

Feb 13 (Reuters) - Catabasis Pharmaceuticals Inc:

* CATABASIS PHARMACEUTICALS REPORTS EDASALONEXENT PRESERVED MUSCLE FUNCTION AND SUBSTANTIALLY SLOWED DUCHENNE MUSCULAR DYSTROPHY DISEASE PROGRESSION THROUGH MORE THAN ONE YEAR OF TREATMENT

* CATABASIS - PLANS TO INITIATE SINGLE GLOBAL PHASE 3 TRIAL WITH EDASALONEXENT IN PATIENTS WITH DMD REGARDLESS OF MUTATION TYPE IN FIRST HALF OF 2018

* CATABASIS PHARMACEUTICALS - EDASALONEXENT CONTINUED TO BE WELL TOLERATED WITH NO SAFETY SIGNALS OBSERVED IN TRIAL

* CATABASIS PHARMACEUTICALS INC - TOP-LINE RESULTS IN SINGLE GLOBAL PHASE 3 TRIAL WITH EDASALONEXENT IN PATIENTS EXPECTED IN 2020 Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up